Israel

Index
Globenewswire

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Globenewswire

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Globenewswire

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Globenewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Globenewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Globenewswire

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Globenewswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Globenewswire

Teva Releases Q4 2025 Aide Memoire

Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Globenewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Globenewswire

Cellebrite Completes Acquisition of Corellium, Extending the Industry’s Most Advanced AI-Powered Digital Investigation Platform

Globenewswire

Teva Receives European Commission Approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Globenewswire

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Globenewswire

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Globenewswire

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

Globenewswire

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Globenewswire

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Globenewswire

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Globenewswire

Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

Globenewswire

Actor, Host, Artist and Anti-Human Trafficking Advocate Terry Crews to Headline Cellebrite C2C User Summit 2026

Globenewswire

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Globenewswire

Cellebrite Expands Market Reach with Innovations in Agentic AI, Cloud and Device Virtualization for the Company’s Autumn 2025 Release

Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Globenewswire

Teva Releases Q3 2025 Aide Memoire

Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025